Brought to you by 
Series D brings in hefty $38mm for Alder Biopharmaceuticals
19 Apr 2012
Executive Summary
Alder Biopharmaceuticals Inc. (developing therapeutics aimed at cancer, pain, and cardiovascular, autoimmune, and inflammatory diseases) has raised $38mm through its Series D financing led by first-time backer Novo Ventures, which adds a board member. Returning shareholders Sevin Rosen Funds, Ventures West, WRF Capital, HIG Ventures, Delphi Ventures, and TPG Biotech also participated. Funds will support ongoing clinical trials of its Phase II ALD518 in cancer and Phase I ALD403 for migraines, and preclinical development of ALD306 for dyslipidemia. The company raised $40mm in its January 2008 Series C round.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D brings in hefty $38mm for Alder Biopharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice